Purine analogue combinations for indolent lymphomas

Seminars in Hematology

Volumn 43, Issue SUPPL. 2, 2006, Pages

  Di Bella, Nicholas ^a   Ravandi, Farhad ^b  

^a ROCKY MOUNTAIN CANCER CENTERS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ALKYLATING AGENT; ALPHA2A INTERFERON; ANTIBIOTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; CLADRIBINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; MITOXANTRONE; NUCLEOSIDE DERIVATIVE; PENTOSTATIN; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CYTOTOXICITY; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG INHIBITION; DRUG POTENTIATION; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; GRANULOCYTOPENIA; HAIRY CELL LEUKEMIA; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INFECTION; LEUKOPENIA; LYMPHATIC LEUKEMIA; LYMPHOCYTOPENIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; REVIEW; SURVIVAL; THROMBOCYTOPENIA; VOMITING;

EID: 33644955611     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2005.12.006     Document Type: Article

References (93)

1. A. Jemal, T. Murray, E. Ward, A. Samuels, R.C. Tiwari, A. Ghafoor Cancer statistics, 2005 CA Cancer J Clin 55 2005 10 30
2. J.M. Vose, B.C. Chiu, B.D. Cheson, J. Dancey, J. Wright Update on epidemiology and therapeutics for non-Hodgkin's lymphoma Hematology (Am Soc Hematol Educ Program) 2002 241 262
3. S.A. Pileri, P.L. Zinzani, P. Went, A. Pileri Jr, M. Bendandi Indolent lymphoma The pathologist's viewpoint Ann Oncol 15 2004 12 18
4. N.L. Harris, E.S. Jaffe, H. Stein, P.M. Banks, J.K. Chan, M.L. Cleary A revised European-American classification of lymphoid neoplasms A proposal from the International Lymphoma Study Group Blood 84 1994 1361 1392
5. N.L. Harris, E.S. Jaffe, J. Diebold, G. Flandrin, H.K. Muller-Hermelink, J. Vardiman World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues Report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997 J Clin Oncol 17 1999 3835 3849
6. J.O. Armitage Treatment of non-Hodgkin's lymphoma N Engl J Med 328 1993 1023 1030
7. F.D. Groves, M.S. Linet, L.B. Travis, S.S. Devesa Cancer surveillance series Non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995 J Natl Cancer Inst 92 2000 1240 1251
8. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project Blood 89 1997 3909 3918
9. J.N. Winter, R.D. Gascoyne, K. Van Besien Low-grade lymphoma Hematology (Am Soc Hematol Educ Program) 2004 203 220
10. P. Solal-Celigny, P. Roy, P. Colombat, J. White, J.O. Armitage, R. Arranz-Saez Follicular lymphoma international prognostic index Blood 104 2004 1258 1265
11. S.J. Horning Natural history of and therapy for the indolent non-Hodgkin's lymphomas Semin Oncol 20 1993 75 88
12. T.P. Miller, S. Dahlberg, J.R. Cassady, D.J. Adelstein, C.M. Spier, T.M. Grogan Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma N Engl J Med 339 1998 21 26
13. B.D. Cheson New chemotherapeutics strategies for the treatment of indolent lymphoid malignancies Semin Hematol 36 1999 26 33
14. C.E. Dearden, E. Matutes, B.L. Hilditch, G.J. Swansbury, D. Catovsky Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine Br J Haematol 106 1999 515 519
15. I.W. Flinn, K.J. Kopecky, M.K. Foucar, D. Head, J.M. Bennett, R. Hutchison Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin Blood 96 2000 2981 2986
16. Y. Cohen, P. Solal-Celigny, A. Polliack Rituximab therapy for follicular lymphoma A comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance Haematologica 88 2003 811 823
17. J.D. Hainsworth, S. Litchy, H.A. Burris 3rd, D.C. Scullin Jr, S.W. Corso, D.A. Yardley Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma J Clin Oncol 20 2002 4261 4267
18. L.E. Robertson, S. Chubb, R.E. Meyn, M. Story, R. Ford, W.N. Hittelman Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine Blood 81 1993 143 150
19. H.M. Kantarjian, J. Schachner, M.J. Keating Fludarabine therapy in hairy cell leukemia Cancer 67 1991 1291 1293
20. E.R. Giblett, J.E. Anderson, F. Cohen, B. Pollara, H.J. Meuwissen Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity Lancet 2 1972 1067 1069
21. M. Grever, K. Kopecky, M.K. Foucar, D. Head, J.M. Bennett, R.E. Hutchison Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia an intergroup study J Clin Oncol 13 1995 974 982
22. D. Catovsky, E. Matutes, J.G. Talavera, N.T. O'Connor, S.A. Johnson, E. Emmett Long term results with 2'deoxycoformycin in hairy cell leukemia Leuk Lymphoma 14 suppl 1 1994 109 113
23. A. Saven, C. Burian, J.A. Koziol, L.D. Piro Long-term follow-up of patients with hairy cell leukemia after cladribine treatment Blood 92 1998 1918 1926
24. G.R. Goodman, E. Beutler, A. Saven Cladribine in the treatment of hairy-cell leukaemia Best Pract Res Clin Haematol 16 2003 101 116
25. M.R. Grever, C.A. Doan, E.H. Kraut Pentostatin in the treatment of hairy-cell leukemia Best Pract Res Clin Haematol 16 2003 91 99
26. A.S. Spiers, S.J. Parekh, M.B. Bishop Hairy-cell leukemia Induction of complete remission with pentostatin (2′-deoxycoformycin) J Clin Oncol 2 1984 1336 1342
27. R.N. Brogden, E.M. Sorkin Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders Drugs 46 1993 652 677
28. A. Cohen, R. Hirschhorn, S.D. Horowitz, A. Rubinstein, S.H. Polmar, R. Hong Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency Proc Natl Acad Sci U S A 75 1978 472 476
29. P.L. Zinzani Non-Hodgkin's lymphoma The evolving role of purine analogues Best Pract Res Clin Haematol 15 2002 505 516
30. S. Seto, C.J. Carrera, M. Kubota, D.B. Wasson, D.A. Carson Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes J Clin Invest 75 1985 377 383
31. W. Sheridan, D.S. Gordon, A.J. Fullen, A. Olson, W.R. Vogler, E. Winton Preclinical studies on deoxycoformycin and deoxyadenosine as pharmacologic T cell purging tools Bone Marrow Transplant 4 1989 511 517
32. M.T. Aye, J.V. Dunne Effect of 2′-deoxycoformycin on erythroid, granulocytic, and T-lymphocyte colony growth Blood 58 1981 1043 1046
33. + lymphocyte counts in patients with hairy cell leukemia Blood 83 1994 2906 2911
34. S. O'Brien, H. Kantarjian, M. Beran, T. Smith, C. Koller, E. Estey Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment Blood 82 1993 1695 1700
35. + T cells in peripheral blood of deoxycoformycin-treated patients J Natl Cancer Inst 83 1991 1678 1679
36. H.S. Hochster, K.M. Kim, M.D. Green, R.B. Mann, R.S. Neiman, M.M. Oken Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma Results of an Eastern Cooperative Oncology Group study J Clin Oncol 10 1992 28 32
37. J.R. Redman, F. Cabanillas, W.S. Velasquez, P. McLaughlin, F.B. Hagemeister, F. Swan Jr Phase II trial of fludarabine phosphate in lymphoma an effective new agent in low-grade lymphoma J Clin Oncol 10 1992 790 794
38. W. Hiddemann, M. Unterhalt, C. Pott, B. Wormann, D. Sandford, M. Freund Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas A phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group Semin Oncol 20 1993 28 31
39. C.I. Falkson Fludarabine A phase II trial in patients with previously treated low-grade lymphoma Am J Clin Oncol 19 1996 268 270
40. J.S. Whelan, C.L. Davis, S. Rule, M. Ranson, O.P. Smith, A.B. Mehta Fludarabine phosphate for the treatment of low grade lymphoid malignancy Br J Cancer 64 1991 120 123
41. C. Tondini, M. Balzarotti, I. Rampinelli, P. Valagussa, M. Luoni, A. De Paoli Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma A phase II randomized study Ann Oncol 11 2000 231 233
42. P.L. Zinzani, F. Lauria, D. Rondelli, D. Benfenati, D. Raspadori, M. Bocchia Fludarabine an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma Ann Oncol 4 1993 575 578
43. A. Saven, S. Emanuele, M. Kosty, J. Koziol, D. Ellison, L. Piro 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma Blood 86 1995 1710 1716
44. D.C. Betticher, A. von Rohr, D. Ratschiller, S.F. Schmitz, T. Egger, T. Sonderegger Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma J Clin Oncol 16 1998 850 858
45. J. Mercieca, E. Matutes, C. Dearden, K. MacLennan, D. Catovsky The role of pentostatin in the treatment of T-cell malignancies Analysis of response rate in 145 patients according to disease subtype J Clin Oncol 12 1994 2588 2593
46. F.J. Cummings, K. Kim, R.S. Neiman, R.L. Comis, M.M. Oken, S.A. Weitzman Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease J Clin Oncol 9 1991 565 571
47. D.B. Duggan, J.R. Anderson, R. Dillman, D. Case, A.J. Gottlieb 2′ Deoxycoformycin (pentostatin) for refractory non-Hodgkin's lymphoma A CALGB phase II study Med Pediatr Oncol 18 1990 203 206
48. S. Monfardini, R. Sorio, F. Cavalli, T.H. Cerny, M. Van Glabbeke, S. Kaye Pentostatin (2′-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 1996 163 168
49. P. McLaughlin, F.B. Hagemeister, J.E. Romaguera, A.H. Sarris, O. Pate, A. Younes Fludarabine, mitoxantrone, and dexamethasone An effective new regimen for indolent lymphoma J Clin Oncol 14 1996 1262 1268
50. P. McLaughlin, F.B. Hagemeister, F. Swan Jr, F. Cabanillas, O. Pate, J.E. Romaguera Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma J Clin Oncol 12 1994 575 579
51. P.L. Zinzani, M. Bendandi, M. Magagnoli, F. Gherlinzoni, E. Merla, S. Tura Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma Ann Oncol 8 1997 379 383
52. R. Bordonaro, G. Petralia, N. Restuccia, A.M. Todaro, D. Serraino, D. Giuffrida Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors Results of a phase II study Leuk Lymphoma 45 2004 93 100
53. A.M. Tsimberidou, P. McLaughlin, A. Younes, M.A. Rodriguez, F.B. Hagemeister, A. Sarris Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma Blood 100 2002 4351 4357
54. A.M. Tsimberidou, A. Younes, J. Romaguera, F.B. Hagemeister, M.A. Rodriguez, L. Feng Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen Cancer 104 2005 345 353
55. P.L. Zinzani, M. Magagnoli, M. Bendandi, F. Gherlinzoni, G.F. Orcioni, C. Cellini Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas Ann Oncol 11 2000 363 365
56. J.F. Seymour, A.P. Grigg, J. Szer, R.M. Fox Fludarabine and mitoxantrone Effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders Ann Oncol 12 2001 1455 1460
57. C. Emmanouilides, P. Rosen, S. Rasti, M. Territo, L. Kunkel Treatment of indolent lymphoma with fludarabine/mitoxantrone combination A phase II trial Hematol Oncol 16 1998 107 116
58. W.S. Velasquez, D. Lew, T.M. Grogan, C.H. Spiridonidis, S.P. Balcerzak, S.R. Dakhil Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma S9501 J Clin Oncol 21 2003 1996 2003
59. M.A. Dimopoulos, G. Fountzilas, E. Papageorgiou, C. Kiamouris, G. Mantzios, A. Anagnostopoulos Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone A phase II study of the Hellenic Cooperative Oncology Group Leuk Lymphoma 43 2002 111 114
60. I.S. Lossos, O. Paltiel, A. Polliack Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas Leuk Lymphoma 33 1999 155 160
61. M. Lazzarino, E. Orlandi, M. Montillo, A. Tedeschi, G. Pagnucco, C. Astori Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma Ann Oncol 10 1999 59 64
62. S.M. O'Brien, H.M. Kantarjian, J. Cortes, M. Beran, C.A. Koller, F.J. Giles Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia J Clin Oncol 19 2001 1414 1420
63. J. Eucker, C. Schille, P. Schmid, C. Jakob, J. Schetelig, D. Kingreen The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas Anticancer Drugs 13 2002 907 913
64. C.S. Tam, M.M. Wolf, E.H. Januszewicz, H.M. Prince, D. Westerman, J.F. Seymour Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies Cancer 100 2004 2181 2189
65. N. Rohatgi, R.V. LaRocca, V. Bard, G. Sethuraman, K.A. Foon Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas Am J Hematol 70 2002 181 185
66. G. Santini, T. Chisesi, S. Nati, A. Porcellini, V. Zoli, V. Rizzoli Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma A report from the non-Hodgkin's lymphoma co-operative study group Leuk Lymphoma 45 2004 1141 1147
67. L. Hendry, A. Bowen, E. Matutes, J. Swansbury, D. Catovsky Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma Leuk Lymphoma 45 2004 945 950
68. G. Santini, S. Nati, M. Spriano, A. Gallamini, D. Pierluigi, A.M. Congiu Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma Haematologica 86 2001 282 286
69. N. Di Gaetano, Y. Xiao, E. Erba, R. Bassan, A. Rambaldi, J. Golay Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone Br J Haematol 114 2001 800 809
70. D.G. Savage, N.S. Cohen, C.S. Hesdorffer, D. Heitjan, M.W. Oster, T.J. Garrett Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia Leuk Lymphoma 44 2003 477 481
71. M.S. Czuczman, A. Koryzna, A. Mohr, C. Stewart, K. Donohue, L. Blumenson Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma J Clin Oncol 23 2005 694 704
72. R. Forstpointner, M. Dreyling, R. Repp, S. Hermann, A. Hanel, B. Metzner The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood 104 2004 3064 3071
73. A. Saven, T. Lee, M. Kosty, L. Piro Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma J Clin Oncol 14 1996 2139 2144
74. M.J. Rummel, K.U. Chow, T. Karakas, E. Jager, J. Mezger, U. von Grunhagen Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma Eur J Cancer 38 2002 1739 1746
75. T. Robak, J. Gora-Tybor, H. Urbanska-Rys, E. Krykowski Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma Leuk Lymphoma 32 1999 359 363
76. F.M. Laurencet, G.B. Zulian, M. Guetty-Alberto, P.A. Iten, D.C. Betticher, P. Alberto Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies Br J Cancer 79 1999 1215 1219
77. T. Robak, J. Gora-Tybor, E. Lech-Maranda, J.Z. Blonski, M. Kasznicki Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies Eur J Haematol 66 2001 188 194
78. T. Robak, P. Smolewski, H. Urbanska-Rys, J. Gora-Tybor, J.Z. Blonski, M. Kasznicki Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies Leuk Lymphoma 45 2004 937 944
79. W.H. Wilson Chemotherapy sensitization by rituximab Experimental and clinical evidence Semin Oncol 27 2000 30 36
80. R. Drapkin, N.J. Di Bella, D.C. Faragher, E. Harden, C. Matei, W. Hyman Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma an effective and minimally toxic regimen Clin Lymphoma 4 2003 169 175
81. N. Di Bella, C. Reynolds, D. Faragher, J. Muscato, K.A. Boehm, L. Asmar An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, stage III or IV, low-grade non-Hodgkin lymphoma Cancer 103 2005 978 984
82. M. Ghielmini, S.F. Schmitz, S.B. Cogliatti, G. Pichert, J. Hummerjohann, U. Waltzer Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule Blood 103 2004 4416 4423
83. M. Federico, V. Callea, R. Danesi, A. Montanini, N. Di Renzo, M. Petrini Mitoxantrone, prednisone, pentostatin and bleomycin for patients with indolent non-Hodgkin's lymphoma relapsed or unresponsive to previous treatments. Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi (GISL) Cancer Ther 1 2003 63 70
84. R. Buckstein, N. Pennell, N.L. Berinstein What is remission in follicular lymphoma and what is its relevance? Best Pract Res Clin Haematol 18 2005 27 56
85. J.G. Gribben, D. Neuberg, A.S. Freedman, C.D. Gimmi, K.W. Pesek, M. Barber Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma Blood 81 1993 3449 3457
86. P. McLaughlin, F.B. Hagemeister, F. Swan, F. Cabanillas, J. Romaguera, M.A. Rodriguez Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma High remission rates and reversion to negative of peripheral blood bcl-2 rearrangement Ann Oncol 5 suppl 2 1994 73 77
87. A. Lopez-Guillermo, F. Cabanillas, P. McLaughlin, T. Smith, F. Hagemeister, M.A. Rodriguez The clinical significance of molecular response in indolent follicular lymphomas Blood 91 1998 2955 2960
88. A. Lopez-Guillermo, F. Cabanillas, P. McLaughlin, T. Smith, F. Hagemeister, M.A. Rodriguez Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma Update of the MDACC series Ann Oncol 11 suppl 1 2000 137 140
89. A. Lopez-Guillermo, F. Cabanillas, T.I. McDonnell, P. McLaughlin, T. Smith, W. Pugh Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma Blood 93 1999 3081 3087
90. A. Rambaldi, M. Lazzari, C. Manzoni, E. Carlotti, L. Arcaini, M. Baccarani Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma Blood 99 2002 856 862
91. C.G. Price, J. Meerabux, S. Murtagh, F.E. Cotter, A.Z. Rohatiner, B.D. Young The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma J Clin Oncol 9 1991 1527 1532
92. A.C. Lambrechts, P.E. Hupkes, L.C. Dorssers, M.B. van't Veer Clinical significance of t(14; 18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission J Clin Oncol 12 1994 1541 1546
93. W.T. Swenson, J.E. Wooldridge, C.F. Lynch, V.L. Forman-Hoffman, E. Chrischilles, B.K. Link Improved survival of follicular lymphoma patients in the United States J Clin Oncol 23 2005 5019 5026